NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined 0.6%, while the Danish biotech stocks increased 5.6%. Genmab, IO Biotech, Ascendis Pharma, and Evaxion Biotech presented encouraging study results with IO Biotech in strong rebound.
12 of the 22 Danish biotech companies had a positive share price development the past week and 11 companies have had a positive share price performance year-to-date. Obesity is still driving the best performances with Gubra and Phila Pharma with strong YTD performance. Six Danish healthcare stocks with +100% YTD return.
Danish company news
No news the past week
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs (Link)
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo (Link)
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 (Link)
No news the past week
No news the past week
CS MEDICA Announces Approval of CANNASEN® Pain Patch in Malaysia and Trademark Registration in Thailand (Link)
CS MEDICA A/S Announces Strategic Partnership with Scan MedPartners to Expand Reach into the US Market (Link)
Commencement of subscription period in Curasight’s preferential rights issue (Link)
Number of Reported Suspected Adverse Reactions Drops by Two-Thirds in 2023 Despite 72% Growth in the Medicinal Cannabis Pilot Programme (Link)
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction (Link)
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 (Link)
No news the past week
No news the past week
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial (Link)
Major shareholder announcement (Link)
No news the past week
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer (Link)
No news the past week
Saniona Receives Regulatory Approval for SAN711 Biomarker Study (Link)
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a return of 5.6%. Many companies reported positive study data. IO Biotech rose 50% following positive phase II data for the treatment of advanced head and neck cancer. Furthermore, Ascendis Pharma presented positive data for TransCon with the achievement of primary objective and being superior to placebo, while Genmab and Evaxion also presented encouraging study results. Additionally, CS Medica received approval for CANNASEN pain patch in Malaysia and a trademark in Thailand. Saniona received approval for a biomarker study for SAN711.
Gubra continues to be the best-performing stock year-to-date with a return of 305%. Y-mAbs Therapeutics, Pila Pharma, Cessatech, Zealand Pharma, and CS Medica have also generated returns of over 100% in 2024.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 0.6% to 68,32. The index has had a strong performance since the beginning of October last year and it has now not only surpassed the KPNGX index but it has also joined the larger indexes in terms of performance. In the past 12 months, the KPHC index has still underperformed relative to large caps, while it has outperformed the broader Nordic growth exchanges by quite a lot.
Price charts for the KPHC, KPNGX, C25, and S30 index for the past twelve months
30-55% in weekly return for the Nordic healthcare stocks
Tendo AB (55%) is a medical technology company that develops medical technology robotic aids for spinal cord injury. The company’s products mainly include Tendo OneGrip, a glove with a so-called integrated exoskeleton that assists people with limited hand function as a result of a spinal cord injury.
NanoEcho AB (46%) is active in healthcare, with a main focus in rectal cancer diagnostics. The company is active in the clinical stage, where a new diagnostic method is being developed to determine whether early rectal cancer has spread to nearby lymph nodes. The method aims to provide a correct diagnosis and individualized treatment. The stock rose following news of approval from the Swedish Medical Products Agency for the use of the iron oxide-based nanoparticle in a planned clinical study
Aino Health AB (30%) is a SaaS company that offers a cloud platform for data-driven corporate health. The platform contains services on a subscription basis to increase well-being and productivity and reduce sickness absence in large, complex organizations and companies. The customers mainly consist of international companies and the public sector.
Sources: Refinitiv Eikon, Cision, Nordnet & company websites.
